American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Pub.; 2013.
2.
CetinM: Clozaphobia: Fear of prescribers of clozapine for treatment of schizophrenia. Bull Clin Psychopharmacol, 24:295–301, 2014.
3.
CouchmanL, MorganPE, SpencerEP, FlanaganRJ: Plasma clozapine, norclozapine, and the clozapine: Norclozapine ratio in relation to prescribed dose and other factors: Data from a therapeutic drug monitoring service, 1993–2007. Ther Drug Monit, 32:438–447, 2010.
4.
HaasSJ, HillR, KrumH, LiewD, TonkinA, DemosL, et al.: Clozapine-associated myocarditis: A review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993–2003. Drug Saf, 30:47–57, 2007.
5.
HaddadPM, AndersonIM: Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs, 62:1649–1671, 2002.
6.
HowesOD, McCutcheonR, AgidO, de BartolomeisA, van BeverenNJ, BirnbaumML, et al.: Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry, 174:218–229, 2017.
7.
LaylandJJ, LiewD, PriorDL: Clozapine-induced cardiotoxicity: A clinical update. Med J Aust, 190:190–192, 2009.
8.
McClellanJ, WerryJ: Practice parameters for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry, 33:616–635, 1994.
9.
MunshiTA, VolochnioukD, HassanT, MazharN: Clozapine-induced myocarditis: Is mandatory monitoring warranted for its early recognition?. Case Rep Psychiatry, 2014:513108, 2014.
10.
SchatzbergAF, NemeroffCB: The American Psychiatric Publishing Textbook of Psychopharmacology (Schatzberg, American Psychiatric Publishing Textbook of Psychopharmacology), 4th ed. Arlington, VA, American Psychiatric Pub., 2009.
